Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending May 15, 2003. The report details corporate actions regarding share re-purchases and updates on directors' interests in company shares.
Key Financial Metrics
The filing does not provide financial performance data such as revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on capital structure transactions and equity movements.
Material Changes and Transactions
- Share Re-purchase: On May 15, 2003, the company purchased 1,100,000 ordinary shares for cancellation at a price of 1304.2626p per share, utilizing authority granted at the Annual General Meeting on May 20, 2002.
- Directors' Interests: The GSK Trust transferred 3,094 ordinary shares on May 12, 2003, and 2,134 ordinary shares on May 13, 2003, to participants in the SmithKline Beecham Employee Share Option Plan 1991.
Guidance, Outlook, and Risks
The filing contains no management commentary, financial guidance, outlook, risk factors, or discussion of contingencies and unusual items.
Investor Verification Points
- Verify the total cost of the 1,100,000 share re-purchase against the stated price of 1304.2626p per share.
- Confirm the remaining share buyback authority available to the company following this transaction.
- Review the impact of the share cancellations on the company's total outstanding share count.